Dolby Family Ventures writes first check into Monument Biosciences



Comments are closed.

QurAlis Closes $88 Million Series B to Advance Precision Medicines for Neurodegenerative Diseases
Tempo Automation Raises $45 Million Series C
Tetra Therapeutics announces positive topline results from Phase 2 study of BPN14770 in patients with Fragile X Syndrome
Twelve, Formerly Opus 12, Secures $57 Million in Series A Funding Led by Capricorn and Carbon Direct